October 27, 2016

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Verseon, a technology-based pharmaceutical company, announces that on 25 October 2016, Mr. Grover Wickersham, Non-Executive Director of the Company, has been issued a grant of restricted stock units (“RSUs”) that relate to payment of his Director’s fees in the form of restricted stock. Dr. Wickersham’s restricted stock grant totals 15,463 Common Shares and is calculated by reference to the closing price on 25 October 2016 of the Company’s common shares in USD, being $1.94. The RSUs vest quarterly in equal proportions over a 6 month period starting from 30 October 2016.

-Ends-

For further information please contact:

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai
   
Cenkos (NOMAD and Broker) +44 (0) 20 7397 8900
Mark Connelly / Steve Cox  
   
Buchanan (PR Advisors) +44 (0) 20 7466 5000
Henry Harrison-Topham / Sophie Cowles
1Details of the person discharging managerial responsibilities / person closely associated
a)NameMr Grover Wickersham
2Reason for the notification
a)Position/statusNon-Executive Director
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerseon Corporation
b)LEIN/A
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Restricted stock grant of Common Shares of par value $0.001

ISIN: USU9221J1098
b)Nature of the transactionIssuance of restricted stock units
c)Price(s) and volume(s)
Prices(s)Volume(s)
$1.9415,463
d)Aggregated information
— Aggregated volume
— Price

15,463
$1.94
e)Date of the transaction25 October 2016
f)Place of the transactionN/A

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen